AgriChem Chronicle

Introduction

On March 16, 2026, China's State Administration for Market Regulation approved and released the first national standard for recombinant protein reagent testing—GB/T47145-2026. This standard, which will take effect on May 1, 2026, specifies the principles, reagent requirements, operational procedures, and result determination rules for affinity measurement. Developed with contributions from companies like Zhejiang Kang Bai Yu, this standard fills a global gap in quality control methods for recombinant proteins. It is expected to significantly enhance the efficiency of registration, quality control (QC) acceptance, and third-party testing mutual recognition for Chinese biological reagents (such as cytokines, fusion proteins, and enzyme-labeled reagents) in markets like Europe, America, Southeast Asia, and the Middle East. This development is particularly relevant for the biopharmaceutical, diagnostic, and research reagent industries, as it standardizes critical quality assessment processes.

Event Overview

The newly released GB/T47145-2026 standard provides a unified methodology for measuring the affinity of recombinant protein reagents, a critical parameter in biopharmaceutical and diagnostic applications. The standard outlines technical requirements, experimental procedures, and validation criteria, ensuring consistency across laboratories and manufacturers. Its implementation date is set for May 1, 2026, giving stakeholders a transition period to adapt their processes.

Impact on Key Sub-Sectors

Biopharmaceutical Manufacturers

For companies producing biologics such as monoclonal antibodies or therapeutic proteins, this standard streamlines QC processes and reduces validation hurdles in international markets. Compliance with the standard may expedite regulatory approvals in regions like the EU and ASEAN, where standardized testing protocols are prioritized.

Diagnostic Reagent Suppliers

Diagnostic kit manufacturers relying on recombinant proteins (e.g., ELISA reagents) will benefit from clearer affinity measurement guidelines, reducing batch-to-batch variability and improving product reliability for end-users.

Contract Research Organizations (CROs)

CROs conducting preclinical or analytical testing must align their protocols with the new standard to maintain credibility with global clients, particularly for cross-border data mutual recognition.

Actionable Insights for Stakeholders

1. Review and Adapt QC Protocols

Manufacturers should audit existing affinity measurement methods against the standard’s requirements, focusing on reagent specifications and operational details outlined in Section 4.2 of GB/T47145-2026.

2. Monitor International Recognition

Track adoption by regulatory bodies in target markets (e.g., EMA, FDA, and ASEAN agencies) to anticipate documentation updates for registration dossiers.

3. Engage in Early Training

Invest in technician training for standardized procedures to minimize transition disruptions before the May 2026 implementation deadline.

Industry Perspective

From an industry standpoint, this standard represents a strategic move to elevate China’s role in global biotech supply chains. While its immediate effect is methodological harmonization, the long-term impact could include increased trust in Chinese-origin biological reagents. However, actual market gains will depend on how swiftly international regulators incorporate the standard into their frameworks. Companies should treat this as a foundational step rather than an immediate market differentiator.

Conclusion

The GB/T47145-2026 standard marks a significant advancement in quality control for recombinant protein reagents, addressing a previously unstandardized global niche. For industry players, proactive adaptation—rather than reactive compliance—will be key to leveraging this development for competitive advantage in international markets.

Sources

• State Administration for Market Regulation (SAMR) Announcement, March 16, 2026
• GB/T47145-2026 Standard Documentation (Draft for Implementation)

Note: The standard’s adoption rate by international regulators remains to be observed post-implementation.